This observational study (n=5000) will examine adults with depressed mood who are receiving esketamine, conventional rTMS, or SAINT as part of routine care, with the aim of assessing the feasibility and clinical utility of predictive models of treatment response built from multimodal clinical data. It will use integrated real-world datasets to explore whether personalised tools could help guide treatment selection in depression. Participants must be 18 years or older, able to give informed consent, and prescribed one of the listed treatments in standard clinical practice. The main outcome is the Patient Health Questionnaire 9-item (PHQ-9), measured pre-treatment, post-treatment, 2 weeks after treatment, and then monthly for 12 months. Retrospective clinical and research data from existing databases may also be included, where available and authorised, to support model development and validation.
This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings. The study will examine outcomes among patients treated with interventions including esketamine, conventional transcranial magnetic stimulation (TMS), or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). Retrospective clinical and research data from existing databases may also be incorporated, when available and authorized, to support model development and validation. The goal is to assess whether integrated clinical datasets can be used to support the development of predictive tools that may inform personalized treatment selection in depression.
Patients receiving esketamine for the treatment of depressed mood.
Patients receiving conventional rTMS for the treatment of depressed mood.
Patients receiving SAINT for the treatment of depressed mood.